Clinical trialNCT00129948TerminatedPhase 2Interventional

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

SponsorSGX Pharmaceuticals, Inc.Enrollment211Leukemia, Myeloid, Acute

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 2, single-arm, open-label, multi-center study to establish the safety and efficacy of Troxatyl™ (troxacitabine) administered as a continuous infusion for 5 days to subjects with AML.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Francis Giles, MD
M.D. Anderson Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Scripps Clinic
La Jolla, California, United States
Usc-Norris Neuro-Oncology Program
Los Angeles, California, United States
Ucsd Moores Cancer Center
San Diego, California, United States
Univ. of Florida, Baptist Cancer Center
Jacksonville, Florida, United States
Winship Cancer Institute, Emory University Hosp.
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Loyola University Medical Center
Maywood, Illinois, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Harper Hospital - Karmanos Cancer Center
Detroit, Michigan, United States
Univ. of Minnesota Medical Center
Minneapolis, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
New York Presbyterian Hospital-Cornell Campus
New York, New York, United States
Wake Forest Univ. School of Medicine
Winston-Salem, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Univ. of South Carolina, Hematology/oncology Division
Charleston, South Carolina, United States
Univ. of Texas, Md Anderson Cancer Center
Houston, Texas, United States
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, United States
Morgantown Internal Medicine Group
Morgantown, West Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Troxatyl™

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2005
Primary completion: —
Completion: 31 Oct 2007
Last update posted: 3 Nov 2006
Registered enrollment: 211
Registry id: NCT00129948

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.